Compass Pathways soars as psilocybin depression treatment hits second Phase 3 trial goals Endpoints NewsCompass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials Yahoo FinanceCompass says its psilocybin drug helped patients with severe depression in two trials statnews.comCompass guides psychedelic therapy to 2nd pivotal depression win, triggering approval push Fierce BiotechCompass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression Business Wire
